Floatz logo

Vtx-2337

Epithelial Ovarian Cancer

CelgenePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
73/ 100

Competitive context

245 Active assets in the Epithelial Ovarian Cancer cohort.

Asset / SponsorPhaseRating
Trabectedin
AGO Research GmbH
Phase 4BBB
Mirvetuximab Soravtansine
AstraZeneca
Phase 3BBB
Olaparib
Imunon
Phase 4BB
Irinotecan
OHSU Knight Cancer Institute
Phase 2BB
Carboplatin
University of Washington
Phase 3BB

View all 50 →

Same molecule, other indications

Vtx-2337 is also rated in:

primary peritoneal carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
fallopian tube cancerDormant
CCC
Indicative ·
48 / 100
View asset →
ovarian seromucinous carcinomaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →